InsidersTradesSigma
Track the 微芯生物 stock price and the full directors' dealings record of the company, a publicly traded company based in China. Shares are quoted on the CN market, under the supervision of SSE / SZSE (CSRC). Operating in the Health Care sector, 微芯生物 has published 3 public disclosures. Market capitalisation: €12bn. The latest transaction was reported on 3 December 2024 (Sale). Among the most active insiders: 山松. The full history is free.
3
Insider Decl.
n/a
Thresholds
n/a
n/a
Buy Volume
€1m
3 ops.
Sell Volume
7Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 18,964 of 29,063 companies
42.0
score / 100
Value35
Quality49
FCF yld-0.7%
Earn yld0.4%
EV/EBITDA·
ROE4.7%
Gross mgn87%
Net mgn5.6%
Debt/EBITDA9.9x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 3 December 2024
关于 微芯生物
微芯生物是一家医疗保健和制药行业的公司，在上海证券交易所上市。它专注于开发创新的生物制药解决方案。